PINK1 and lung adenocarcinoma: From a translational perspective, therapies targeting these pathways, such as PI3K inhibitors or mitophagy modulators like metformin, may hold promise for improving patient outcomes, particularly in those with lung adenocarcinoma and BM exhibiting high PI3K and PINK1 expression [45,46].